Zentalis Pharmaceuticals, LLC(ZNTL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ZNTL Zentalis Pharmaceuticals, LLC

Pre-Mkt 04-16 04:30:08 EDT

5.36

+0.16

+3.08%

盘前5.36

+0.000.00%

04:01 EDT

High5.58	Low4.91	Vol2.56M
Open5.20	D1 Closing5.20	Amplitude12.79%
Mkt Cap380.19M	Tradable Cap260.85M	Total Shares70.93M
T/O13.40M	T/O Rate5.27%	Tradable Shares48.67M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ZNTL","market":"US","secType":"STK","nameCN":"Zentalis Pharmaceuticals, LLC","latestPrice":5.36,"timestamp":1776283200000,"preClose":5.2,"halted":0,"volume":2562548,"hourTrading":{"tag":"盘前","latestPrice":5.36,"preClose":5.36,"latestTime":"04:01 EDT","volume":8,"amount":42.88,"timestamp":1776326463186,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.030769230769230795,"floatShares":48666300,"shares":70931016,"eps":-1.91,"marketStatus":"Pre-Mkt","change":0.16,"latestTime":"04-16 04:30:08 EDT","open":5.2,"high":5.575,"low":4.91,"amount":13398906.4546928,"amplitude":0.127885,"askPrice":6.07,"askSize":100,"bidPrice":4.58,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.91,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1776346200000},"marketStatusCode":1,"adr":0,"listingDate":1585886400000,"exchange":"NASDAQ","adjPreClose":5.36,"preHourTrading":{"tag":"盘前","latestPrice":5.36,"preClose":5.36,"latestTime":"04:01 EDT","volume":8,"amount":42.88,"timestamp":1776326463186,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":5.4,"preClose":5.36,"latestTime":"19:37 EDT","volume":21446,"amount":115341.1575,"timestamp":1776296256841,"change":0.04,"changeRate":0.007463,"amplitude":0.02694},"volumeRatio":0.17820283997790312,"impliedVol":3.9816,"impliedVolPercentile":0.9598},"requestUrl":"/m/hq/s/ZNTL","defaultTab":"news","newsList":[{"id":"2627107955","title":"A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection News","url":"https://stock-news.laohu8.com/highlight/detail?id=2627107955","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627107955?lang=en_us&edition=fundamental","pubTime":"2026-04-13 08:26","pubTimestamp":1776039976,"startTime":"0","endTime":"0","summary":"Zentalis Pharmaceuticals (ZNTL) has drawn fresh investor attention after selecting a 400mg once daily, 5-days-on, 2-days-off azenosertib regimen as the optimal monotherapy dose in platinum resistant ovarian cancer.\nSee our latest analysis for Zentalis Pharmaceuticals.\nThe azenosertib update has arrived alongside intense trading interest, with a 1 day share price return of 49.55% and a year to date share price return of 382.48%. The 1 year total shareholder return sits at 437.40%, but the 3...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zntl/zentalis-pharmaceuticals/news/a-look-at-zentalis-pharmaceuticals-zntl-valuation-after-azen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zntl/zentalis-pharmaceuticals/news/a-look-at-zentalis-pharmaceuticals-zntl-valuation-after-azen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ZNTL","BK4139","DCF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626146111","title":"What's Behind The Surge In Zentalis Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2626146111","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626146111?lang=en_us&edition=fundamental","pubTime":"2026-04-11 00:44","pubTimestamp":1775839440,"startTime":"0","endTime":"0","summary":"Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) shares are surging Friday after a Guggenheim analyst raised the price target from $6 to $10.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/10/Ai-Robot-Hand-Touching-Forex-Charts-And-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/10/Ai-Robot-Hand-Touching-Forex-Charts-And-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/04/51759107/whats-behind-the-surge-in-zentalis-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/04/51759107/whats-behind-the-surge-in-zentalis-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["SMA","BK4139","BK4217","RSI","BK4150","ZNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626113966","title":"Zentalis Pharmaceuticals Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2626113966","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626113966?lang=en_us&edition=fundamental","pubTime":"2026-04-10 21:33","pubTimestamp":1775827980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZNTL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2026 09:33 ET (13:33 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626413135","title":"H.C. Wainwright Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2626413135","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626413135?lang=en_us&edition=fundamental","pubTime":"2026-04-10 00:25","pubTimestamp":1775751933,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Zentalis Pharmaceuticals today and set a price target of $10.00. According t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-zentalis-pharmaceuticals-zntl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-zentalis-pharmaceuticals-zntl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626184921","title":"Zentalis picks 400 mg azenosertib dose for pivotal ovarian cancer trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2626184921","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626184921?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:09","pubTimestamp":1775736545,"startTime":"0","endTime":"0","summary":"Zentalis selected 400 mg once-daily on a 5-days-on, 2-days-off schedule as pivotal monotherapy dose for investigational WEE1 inhibitor azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer.Decision follows a prespecified interim analysis from DENALI Part 2a, with results already reviewed internally rather than separately reported.Interim findings supported a more favorable benefit-risk profile at selected dose versus lower dose, driven by stronger tumor response with similar safety.Selected regimen will be used in ongoing potentially pivotal DENALI Phase 2 trial plus confirmatory ASPENOVA Phase 3 trial.Zentalis expects DENALI Part 2 topline results by year-end 2026, with enrollment expansion planned to start in Q2 2026 to reflect shifting treatment patterns.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL2PYgJ4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","IE00BN0W2W23.USD","BK4585","SG9999014013.SGD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","IE00BKPKM429.USD","SG9999014005.SGD","LU2095319765.USD","SG9999014039.USD","LU0314104364.USD","LU2210149790.SGD","ZNTL","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","BK4139","NDAQ","BK4588","IE00B64PRP62.GBP","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626817761","title":"Zentalis Pharmaceuticals Inc - Denali Part 2 Topline Readout Expected by Year-End 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2626817761","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626817761?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:00","pubTimestamp":1775736002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUA9SWKWC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZNTL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626817651","title":"Zentalis Pharmaceuticals Announces 400Mg Qd 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2626817651","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626817651?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:00","pubTimestamp":1775736002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUA9SWKWC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZNTL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624154288","title":"BRIEF-Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624154288","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624154288?lang=en_us&edition=fundamental","pubTime":"2026-04-02 05:29","pubTimestamp":1775078966,"startTime":"0","endTime":"0","summary":"BRIEF-Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)April 1 (Reuters) - Zentalis Pharmaceuticals Inc ZNTL.O:ZENTALIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nTUACD39SZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZNTL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624544327","title":"Zentalis grants inducement stock options for 36,000 shares to new hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2624544327","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624544327?lang=en_us&edition=fundamental","pubTime":"2026-04-02 05:00","pubTimestamp":1775077223,"startTime":"0","endTime":"0","summary":"Zentalis Pharmaceuticals granted inducement stock options covering 36,000 shares to two newly hired employees on April 1, 2026.Options carry an exercise price of $2.57 per share.Vesting schedule sets 25% on first anniversary, remaining balance in equal monthly installments over next three years.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL2D6xXw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","IE00BN0W2W23.USD","BK4585","SG9999014013.SGD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","IE00BKPKM429.USD","SG9999014005.SGD","LU2095319765.USD","SG9999014039.USD","LU0314104364.USD","LU2210149790.SGD","ZNTL","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","BK4139","NDAQ","BK4588","IE00B64PRP62.GBP","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622290807","title":"Wedbush Keeps Their Hold Rating on Zentalis Pharmaceuticals (ZNTL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622290807","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622290807?lang=en_us&edition=fundamental","pubTime":"2026-03-28 11:56","pubTimestamp":1774670195,"startTime":"0","endTime":"0","summary":"In a report released yesterday, from Wedbush maintained a Hold rating on Zentalis Pharmaceuticals, with a price target of $4.00. The company’s shar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-keeps-their-hold-rating-on-zentalis-pharmaceuticals-zntl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-keeps-their-hold-rating-on-zentalis-pharmaceuticals-zntl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622821012","title":"Zentalis Pharmaceuticals Price Target Maintained With a $6.00/Share by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2622821012","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622821012?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:57","pubTimestamp":1774616220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZNTL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2026 08:57 ET (12:57 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZNTL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622821558","title":"Zentalis Pharmaceuticals (ZNTL) Receives a Buy from Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2622821558","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622821558?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:35","pubTimestamp":1774614937,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Zentalis Pharmaceuticals today and set a price target of $9.00. Biegler covers the H...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/zentalis-pharmaceuticals-zntl-receives-a-buy-from-oppenheimer-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/zentalis-pharmaceuticals-zntl-receives-a-buy-from-oppenheimer-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","BK4127","ZNTL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622899731","title":"Zentalis Pharmaceuticals 2025 Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2622899731","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622899731?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:45","pubTimestamp":1774557919,"startTime":"0","endTime":"0","summary":"Zentalis Pharmaceuticals  late Thursday reported a 2025 loss of $1.91 per diluted share, narrowing from a loss of $2.33 a year earlier.Analysts surveyed by FactSet expected loss of $1.82.As of Dec. 31, the company said it had $245.9 million in cash, cash equivalents and marketable securities, with projected cash runway into late 2027.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ZNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622899147","title":"Zentalis Pharma Q4 EPS $(0.49) Misses $(0.44) Estimate.","url":"https://stock-news.laohu8.com/highlight/detail?id=2622899147","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622899147?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:39","pubTimestamp":1774557564,"startTime":"0","endTime":"0","summary":"Zentalis Pharma (NASDAQ:ZNTL) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.44) by 10.36 percent. This is a 25.76 percent increase over losses of $(0.66) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51496486/zentalis-pharma-q4-eps-0-49-misses-0-44-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Zentalis Pharma Q4 EPS $(0.49) Misses $(0.44) Estimate.","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622962918","title":"Zentalis FY2025 operating loss narrows 20.1% to $152.8 million; loss per share narrows to $1.91","url":"https://stock-news.laohu8.com/highlight/detail?id=2622962918","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622962918?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:11","pubTimestamp":1774555875,"startTime":"0","endTime":"0","summary":"Zentalis published a press release reporting full-year 2025 financial results and operational updates.Net loss attributable to shareholders was USD 137.1 million, or USD 1.91 per share .Research and development expenses fell 36.07% to USD 107.3 million, driven mainly by lower clinical expenses, lab services, drug manufacturing, and personnel costs.General and administrative expenses dropped 56.71% to USD 37.7 million, primarily due to lower personnel expense including reduced non-cash stock-based compensation.Cash, cash equivalents and marketable securities were USD 245.9 million as of Dec. 31, 2025, and Zentalis said this is expected to fund operations into late 2027 as it targets DENALI Part 2a dose confirmation and ASPENOVA Phase 3 initiation in 1H 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL830xlM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZNTL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622969008","title":"Press Release: Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2622969008","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622969008?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:05","pubTimestamp":1774555500,"startTime":"0","endTime":"0","summary":"-- DENALI Part 2 trial topline readout expected by year end 2026; potential. -- On track to initiate the ASPENOVA Phase 3, randomized, confirmatory trial. -- Expanding azenosertib potential in ovarian cancer with the ongoing MUIR. Part 2 trial evaluating the combination of azenosertib and bevacizumab as. as of December 31, 2025, with projected cash runway into late 2027. \"2026 is expected to be a defining year for Zentalis. With a strong financial foundation, we continue to focus on advancing azenosertib, a potentially first-in-class, non-chemotherapy, oral treatment for patients with Cyclin E1-positive PROC -- a group with substantial unmet medical needs.\" Ms. Eastland added.patients at each of two dose levels with an intermittent single, daily. dosing with five days on, two days off dosing schedule: 400","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZNTL","R","BK4022","PROC","BK4232","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620878025","title":"Zentalis Pharmaceuticals Inc  expected to post a loss of 58 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620878025","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620878025?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:10","pubTimestamp":1774005006,"startTime":"0","endTime":"0","summary":"Zentalis Pharmaceuticals Inc  expected to post a loss of58cents a share - Earnings Preview Zentalis Pharmaceuticals Inc ZNTL.OQ ZNTL.O is expected to  show a fall in quarterly revenue when it reports ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N4080VD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZNTL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620403841","title":"Zentalis Pharmaceuticals to present two posters at AACR annual meeting 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620403841","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620403841?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:30","pubTimestamp":1773779454,"startTime":"0","endTime":"0","summary":"Zentalis will present two posters at the American Association for Cancer Research  Annual Meeting in San Diego, California on April 17-22, 2026. One poster session is scheduled for April 19, 2026, 2:00 p.m.-5:00 p.m. PDT. A second poster session is scheduled for April 20, 2026, 2:00 p.m.-5:00 p.m. PDT. Link","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL8wxZfF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","NDAQ","IE00BKPKM429.USD","IE00BN0W2W23.USD","LU2095319765.USD","BK4588","BK4139","LU2210150020.SGD","BK4585","LU2210149790.SGD","SG9999014039.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","SG9999014021.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU0314104364.USD","BK4112","ZNTL","SG9999014005.SGD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610606952","title":"Zentalis Pharmaceuticals PAO and PFO Vincent Vultaggio Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2610606952","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610606952?lang=en_us&edition=fundamental","pubTime":"2026-02-11 10:10","pubTimestamp":1770775858,"startTime":"0","endTime":"0","summary":"Vincent Vultaggio, PAO and PFO of Zentalis Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDL7NLZdk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Zentalis Pharmaceuticals PAO and PFO Vincent Vultaggio Reports Disposal of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZNTL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609348486","title":"Vincent Vultaggio, PAO and PFO, Reports Sale of Zentalis Pharmaceuticals Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2609348486","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609348486?lang=en_us&edition=fundamental","pubTime":"2026-02-05 09:28","pubTimestamp":1770254903,"startTime":"0","endTime":"0","summary":"Vincent Vultaggio, PAO and PFO of Zentalis Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL4rKT3X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vincent Vultaggio, PAO and PFO, Reports Sale of Zentalis Pharmaceuticals Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZNTL"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zentalis.com;ir.zentalis.com","stockEarnings":[{"period":"1week","weight":0.942},{"period":"1month","weight":0.9779},{"period":"3month","weight":0.6962},{"period":"6month","weight":2.5973},{"period":"1year","weight":3.2205},{"period":"ytd","weight":2.9704}],"compareEarnings":[{"period":"1week","weight":0.0354},{"period":"1month","weight":0.0462},{"period":"3month","weight":0.0111},{"period":"6month","weight":0.0535},{"period":"1year","weight":0.3019},{"period":"ytd","weight":0.0264}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics: and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.042332},{"month":2,"riseRate":0.5,"avgChangeRate":0.033871},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.05504},{"month":4,"riseRate":0.5,"avgChangeRate":0.184696},{"month":5,"riseRate":0.5,"avgChangeRate":0.074443},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.096016},{"month":7,"riseRate":0.5,"avgChangeRate":-0.025772},{"month":8,"riseRate":0.333333,"avgChangeRate":0.051305},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.092542},{"month":10,"riseRate":0.5,"avgChangeRate":0.021215},{"month":11,"riseRate":0.5,"avgChangeRate":0.025361},{"month":12,"riseRate":0.5,"avgChangeRate":0.014046}],"exchange":"NASDAQ","name":"Zentalis Pharmaceuticals, LLC","nameEN":"Zentalis Pharmaceuticals, LLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Zentalis Pharmaceuticals, LLC(ZNTL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Zentalis Pharmaceuticals, LLC(ZNTL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Zentalis Pharmaceuticals, LLC,ZNTL,Zentalis Pharmaceuticals, LLC股票,Zentalis Pharmaceuticals, LLC股票老虎,Zentalis Pharmaceuticals, LLC股票老虎国际,Zentalis Pharmaceuticals, LLC行情,Zentalis Pharmaceuticals, LLC股票行情,Zentalis Pharmaceuticals, LLC股价,Zentalis Pharmaceuticals, LLC股市,Zentalis Pharmaceuticals, LLC股票价格,Zentalis Pharmaceuticals, LLC股票交易,Zentalis Pharmaceuticals, LLC股票购买,Zentalis Pharmaceuticals, LLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Zentalis Pharmaceuticals, LLC(ZNTL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Zentalis Pharmaceuticals, LLC(ZNTL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction